Previous close | 2.3000 |
Open | N/A |
Bid | 0.6500 |
Ask | 3.7000 |
Strike | 80.00 |
Expiry date | 2024-12-20 |
Day's range | 2.3000 - 2.3000 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
As of June 2024, the U.S. stock market presents a mixed landscape, with the Dow Jones advancing while sectors like semiconductors weigh heavily on the Nasdaq. Amidst these fluctuations, identifying stocks that are potentially undervalued becomes crucial for investors looking for opportunities that may not yet reflect their intrinsic worth in their current market prices.
Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.